BioNTech Past Earnings Performance
Past criteria checks 0/6
BioNTech's earnings have been declining at an average annual rate of -55.2%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 35.3% per year.
Key information
-55.18%
Earnings growth rate
-55.14%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | -35.25% |
| Return on equity | -6.70% |
| Net Margin | -44.64% |
| Next Earnings Update | 04 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • May 11
BNTX: Pipeline Data Cycle And Leadership Transition Will Drive Future Upside
Analysts have trimmed their average price targets for BioNTech by about $15, reflecting slightly lower revenue growth assumptions, a higher discount rate and a reduced future P/E multiple, partly offset by a stronger profit margin outlook and ongoing focus on the pipeline and leadership transition highlighted in recent research. Analyst Commentary Recent research on BioNTech centers on two big themes, the leadership transition and how quickly the COVID franchise may decline, with both feeding directly into valuation and price targets.Seeking Alpha • May 06
BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans
Summary BioNTech SE is downgraded to Sell due to declining COVID vaccine revenues, leadership exits, and pipeline uncertainty. BNTX faces €531.9m Q1 net loss, expects €2–3bn 2026 revenues, and plans €1bn share buyback amid €16.8bn cash reserves. Major staff cuts and site exits are underway, targeting €500m annual savings to support the oncology pivot. Key pipeline asset pumitamig faces competitive and regulatory hurdles; overall oncology prospects appear insufficient to justify current BNTX stock valuation. Read the full article on Seeking Alpha
Narrative Update • Apr 21
BNTX: Leadership Turnover And Weak COVID Outlook Will Pressure Future Expectations
BioNTech's updated analyst price target has edged lower by about $2 as analysts balance weaker revenue growth expectations with higher projected profit margins and a lower future P/E while digesting leadership changes and a mixed set of recent target revisions across the Street. Analyst Commentary Street research around BioNTech has turned more mixed, with several bearish analysts trimming price targets and flagging execution and leadership risks following the recent Q4 report and guidance update.
Narrative Update • Apr 07
BNTX: Late Stage Oncology Pipeline And Leadership Transition Will Shape Future Upside
Narrative Update The analyst price target for BioNTech has been reduced by around $8, reflecting lower fair value, slightly higher discount rates, softer revenue and margin assumptions, and recent Street commentary that highlights uncertainty around COVID revenue trends and leadership changes, even as several firms still point to an active late stage pipeline and potential data catalysts. Analyst Commentary Recent Street research around BioNTech clusters around two themes, leadership transition and COVID revenue trends, with both bulls and bears updating valuation views based on those factors and the strength of the late stage pipeline.Narrative Update • Mar 23
BNTX: Leadership Transition And Oncology Data Milestones Will Shape Forward Expectations
Narrative Update The updated analyst fair value estimate for BioNTech has moved lower from about $104.35 to $86.35. This reflects reduced Street price targets after the surprise leadership transition, softer 2026 COVID guidance and revenue growth assumptions, and is partly offset by expectations for improved profit margins and a lower forward P/E as analysts continue to highlight the breadth of the pipeline and upcoming data readouts.Narrative Update • Mar 09
BNTX: Oncology Pipeline Progress And Mixed Rating Shifts Will Shape Expectations
Narrative Update Analysts now place BioNTech's fair value at about $104, up from roughly $102. This reflects a recalibration of forecasts after a recent rally and mixed views on the stock, including both downgrades following strong share performance and a prior upgrade that highlighted potential support for a higher future P/E of about 138x versus about 114x before.Narrative Update • Feb 22
BNTX: Oncology Pipeline Progress Will Drive Future Upside Despite Recent Downgrades
Analysts have nudged their average price target for BioNTech slightly lower, trimming fair value from about $139.98 to $139.51. A mix of recent downgrades after the stock's rally and a more cautious view on revenue trends is offsetting a more constructive stance from other firms.Narrative Update • Feb 08
BNTX: Cancer Pipeline And mRNA Platform Will Support Future Upside
Analysts have trimmed their fair value estimate for BioNTech from about $140.80 to roughly $139.98, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions after a mix of recent downgrades and upgrades on the stock. Analyst Commentary Recent Street research on BioNTech shows both optimism and caution, which helps explain the small trim in fair value estimates rather than a more dramatic shift.Analysis Article • Jan 28
BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%
BioNTech SE ( NASDAQ:BNTX ) shareholders would be excited to see that the share price has had a great month, posting a...Narrative Update • Jan 24
BNTX: Cancer Pipeline Progress And Efficiency Gains Will Drive Future Upside
Analysts have nudged their fair value estimate for BioNTech up to about $141 from roughly $139, citing updated models that reflect steadier COVID-19 franchise assumptions, slightly stronger projected profitability, and increased confidence in the cancer pipeline following recent research upgrades. Analyst Commentary Recent Street research on BioNTech highlights a mix of optimism around the cancer pipeline and COVID-19 franchise, alongside some caution around regulatory readthroughs and execution.Narrative Update • Jan 10
BNTX: Stable Covid Franchise And Efficiency Gains Will Support Future Upside Potential
Analysts have raised their fair value estimate for BioNTech to US$139.29 from US$137.91, citing updated models that reflect recent price target changes across the Street, steady COVID-19 franchise performance, and company guidance that is viewed as a sign of improving operating efficiency. Analyst Commentary Street research around BioNTech is mixed, with price targets moving in both directions but generally clustering near the current fair value estimate.Narrative Update • Dec 25
BNTX Covid-19 Cash Flows Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for BioNTech higher to about $174 from roughly $170, citing resilient COVID-19 vaccine revenues, stable pricing dynamics, and improved operating efficiency reflected in recent price target adjustments across the Street. Analyst Commentary Bullish analysts highlight that BioNTech's valuation is increasingly underpinned by evidence of durable COVID-19 vaccine cash flows, with incremental price target raises signaling confidence that earnings power can be sustained beyond near term pandemic dynamics.Narrative Update • Dec 11
BNTX: Stable Covid Franchise And Efficiency Gains Will Drive Future Upside Momentum
Analysts have nudged their price target for BioNTech higher to approximately $138 from about $135, citing better than expected Comirnaty performance, stable COVID-19 franchise dynamics, and improving operating efficiency despite slightly softer long term revenue growth assumptions. Analyst Commentary Street research following the latest quarterly update highlights a mix of optimism on execution and franchise durability, alongside more cautious adjustments to longer term growth expectations.Narrative Update • Nov 08
BNTX: Revenue Stability And Oncology Pipeline Advances Will Drive Upside Momentum
BioNTech's analyst price target saw a small upward revision to $134.78 from $134.58, reflecting updated Q3 performance and ongoing confidence in the company's revenue stability and pipeline progress, according to analysts. Analyst Commentary Analysts recently weighed in on BioNTech following its Q3 performance updates, offering perspectives on both the company's positive momentum and areas where caution may be warranted.Narrative Update • Oct 25
Oncology Pipeline Expansion And Vaccine Policy Shifts Will Shape Future Performance
BioNTech's analyst price target has been adjusted downward by $4 to $130, as analysts cite updates across the biotech sector and recent earnings previews in their reassessment. Analyst Commentary Analysts have provided mixed commentary on BioNTech's outlook, reflecting both the company's execution strengths and areas of caution in their valuations and projections.Narrative Update • Oct 10
mRNA And Oncology Pipeline Will Boost Markets But Face Delays
Analysts have slightly lowered their price target for BioNTech to $134.76 from $135.85. They cite a modest increase in expected profit margin and ongoing momentum in the company's oncology pipeline as key factors behind the adjustment.Analysis Article • Aug 08
The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
It's been a good week for BioNTech SE ( NASDAQ:BNTX ) shareholders, because the company has just released its latest...Analysis Article • Jul 01
Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Mar 17
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
Summary BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ruling, remain pending, which poses short-term headwinds. Nevertheless, BNTX’s robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology. In my view, BioNTech's long-term value depends on management successfully executing their new R&D strategy and potential M&A transactions. Read the full article on Seeking Alpha
New Narrative • Feb 09
Advancing Oncology Pipeline May Drive Future Growth Amid Near-Term Earnings Pressure
Promising oncology assets, improved R&D efficiencies, and strategic partnerships drive potential long-term revenue growth and shareholder value for BioNTech.Seeking Alpha • Jan 23
BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
Summary I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting revenue and profitability. BioNTech's strong balance sheet and innovative mRNA technology show long-term promise, but regulatory and competitive challenges warrant patience before investing. The NAV model indicates BNTX is trading at a premium, reinforcing the hold rating amidst financial and pipeline uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 06
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Summary BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating. Future oncology success hinges on BNT327 and other assets, but substantial data validation is needed before significant gains can be expected. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
BioNTech's Oncology Gamble: High Stakes, Big Potential
Summary BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution. BioNTech's cash reserves and multiple promising oncology candidates support a positive investment outlook, despite recent regulatory challenges. BioNTech remains a high-risk, high-reward investment due to the potential of their oncology pipeline, but clinical breakthroughs are essential for future market performance. Read the full article on Seeking AlphaSeeking Alpha • Aug 20
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Summary Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer; 12-month overall-survival [OS] rate of 69%. Updated data from the open-label phase 2 study, using BNT311 in combination with Keytruda for patients with relapsed/refractory metastatic non-small cell lung cancer, to be presented at the 2024 World Conference September 7th — 10th. Read the full article on Seeking AlphaSeeking Alpha • Aug 06
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Summary BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times. BioNTech's focus is shifting back to its oncology pipeline, with promising programs in development, but signs of genuine breakthrough progress seem to be absent. BioNTech is unlikely to secure an ex-COVID drug approval for another three years, therefore only very patient investors with great faith in the management team will likely be excited about investing in the business today. Read the full article on Seeking AlphaSeeking Alpha • Jun 13
BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Summary BioNTech's revenue soared during the COVID era, but the company faces uncertainty with declining vaccine sales and plans for new oncology-focused products. The company is shifting focus to oncology programs, aiming for multiple late-stage trials and regulatory submissions, and ten indication approvals by 2030. BioNTech's pipeline includes various oncology drugs targeting different proteins in cancer cells, with potential for 10 indication approvals by 2030. In this post I provide a whistle-stop tour of the current pipeline and opportunities relative to where the industry is. I am not especially encouraged, but with COVID funds and management's track record, BioNTech can afford to move at its own pace. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How BioNTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 2,805 | -1,252 | 655 | 2,136 |
| 31 Dec 25 | 2,870 | -1,136 | 624 | 2,105 |
| 30 Sep 25 | 3,153 | -572 | 539 | 2,211 |
| 30 Jun 25 | 2,878 | -345 | 541 | 2,197 |
| 31 Mar 25 | 2,746 | -766 | 587 | 2,272 |
| 31 Dec 24 | 2,751 | -665 | 599 | 2,254 |
| 30 Sep 24 | 3,040 | -467 | 609 | 2,220 |
| 30 Jun 24 | 2,691 | -504 | 612 | 2,168 |
| 31 Mar 24 | 2,730 | 113 | 566 | 1,957 |
| 31 Dec 23 | 3,819 | 930 | 558 | 1,783 |
| 30 Sep 23 | 6,618 | 2,751 | 550 | 1,715 |
| 30 Jun 23 | 9,184 | 4,375 | 550 | 1,559 |
| 31 Mar 23 | 12,213 | 6,238 | 560 | 1,585 |
| 31 Dec 22 | 17,311 | 9,434 | 541 | 1,537 |
| 30 Sep 22 | 18,565 | 10,322 | 556 | 1,299 |
| 30 Jun 22 | 21,191 | 11,748 | 480 | 1,217 |
| 31 Mar 22 | 23,303 | 12,863 | 394 | 1,019 |
| 31 Dec 21 | 18,977 | 10,293 | 327 | 949 |
| 30 Sep 21 | 13,790 | 7,493 | 229 | 935 |
| 30 Jun 21 | 7,770 | 4,072 | 178 | 902 |
| 31 Mar 21 | 2,503 | 1,197 | 139 | 796 |
| 31 Dec 20 | 482 | 15 | 109 | 645 |
| 30 Sep 20 | 165 | -410 | 79 | 453 |
| 30 Jun 20 | 126 | -230 | 63 | 275 |
| 31 Mar 20 | 110 | -192 | 57 | 232 |
| 31 Dec 19 | 109 | -179 | 49 | 227 |
| 30 Sep 19 | 144 | -122 | 53 | 208 |
| 30 Jun 19 | 136 | -116 | 48 | 191 |
| 31 Mar 19 | 132 | -77 | 38 | 168 |
| 31 Dec 18 | 128 | -48 | 32 | 141 |
| 31 Dec 17 | 62 | -86 | 34 | 82 |
Quality Earnings: BNTX is currently unprofitable.
Growing Profit Margin: BNTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNTX is unprofitable, and losses have increased over the past 5 years at a rate of 55.2% per year.
Accelerating Growth: Unable to compare BNTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: BNTX has a negative Return on Equity (-6.7%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 04:23 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNTech SE is covered by 33 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry Gillis | Berenberg |
| Zhiqiang Shu | Berenberg |
| Samuel England | Berenberg |